Will Vivus, Arena go on a DTC binge for their obesity meds?
Just in time for New Year's resolutions, The Financial Times rounds up the latest on a new generation of obesity drugs. Arena Pharmaceuticals ($ARNA) is gearing up for its Belviq launch, while Vivus ($VVUS) is chipping away at the market with its recently launched Qsymia. Is a direct-to-consumer advertising battle up next? Report (reg. req.)